ImmunityBio, Inc. (IBRX) Stock

ImmunityBio, Inc. (IBRX) is a Healthcare stock trading at $7.85 (as of 2026-08-20), with a market capitalization of $8.22B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines aimed at cancers and infectious diseases. Its programs include immunotherapy and cell-therapy approaches such as antibody cytokine fusion proteins, synthetic immunomodulators, and immune-cell and T-cell–based treatments for solid and liquid tumors and pathogens like SARS-CoV-2 and HIV.

Understand ImmunityBio, Inc.: how it makes money

ImmunityBio develops cancer and infectious-disease immunotherapies and vaccines, and it makes money primarily through product revenue (with potential additional revenue sources such as other revenue and collaboration agreements).

The profit engine is dominated by clinical-stage operating losses, with only small product revenue contributing to the financial picture in the latest quarter.

Revenue by segment (latest quarter)
Product$0.0B
Other$0.0B

Business quality (Solid): Reported revenue is extremely small in this period, so operating performance is best read through operating-loss context and program KPIs like ANKTIVA approval footprint rather than margins.

Bull case

  • Early commercialization signal: The company reports Preliminary Net Product Revenue of 0.04 USD_B and Product Revenue of 0.03 USD_B in the latest quarter.
  • Regulatory progress for ANKTIVA: It reports ANKTIVA Approval or Authorization in 34 countries.

Bear case

  • Large operating losses: Operating margin is -157.9%, indicating heavy spending versus the current revenue base.
  • Revenue base appears tiny versus operating scale: Total reported revenue is 0.0B in the latest quarter while operating losses remain very large, making results sensitive to small changes in product sales and approvals.
Valuation — source: SEC EDGAR (first-party)
Price$7.85
Market Cap$8.22B
Price / Sales47.88
FCF Yield-6.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$113.29M
Net Margin-310.2%
Revenue Growth (YoY)668.3%
EPS Growth (YoY)-35.6%
FCF Growth (YoY)-22.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-6.41 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($202.08M)
Institutional Holders Tracked10
Congressional Trades (recent)1
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORichard Gerald Adcock
Employees671
CountryUS
IPO Date2015-07-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Apogee Therapeutics, Inc. (APGE)
  • Kymera Therapeutics, Inc. (KYMR)
  • Krystal Biotech, Inc. (KRYS)
  • Immunovant, Inc. (IMVT)
  • Vaxcyte, Inc. (PCVX)
  • Twist Bioscience Corporation (TWST)
  • CG Oncology, Inc. Common stock (CGON)
  • Scholar Rock Holding Corporation (SRRK)
IBRX earnings history · IBRX institutional & insider holders · IBRX KPIs & operating metrics · IBRX financials · IBRX investor presentations & press releases · IBRX SEC filings · IBRX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.